EGFR and non-small cell lung carcinoma: First- and second-generation tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, and afatinib, are standard therapies for patients with advanced NSCLC harboring mutations in EGFR. These mutations include deletion mutations in exon 19 and the L858R mutation in exon 21 [1, 2].